<?xml version="1.0" encoding="UTF-8"?>
<p>Lastly, antibody glycosylation is essential for maintaining antibody structural conformation which is directly related to the potency of Fc-effector functions [
 <xref rid="B37-viruses-12-00276" ref-type="bibr">37</xref>,
 <xref rid="B42-viruses-12-00276" ref-type="bibr">42</xref>]. Many factors can affect glycosylation patterns, which include age, pregnancy and virus infection [
 <xref rid="B43-viruses-12-00276" ref-type="bibr">43</xref>,
 <xref rid="B44-viruses-12-00276" ref-type="bibr">44</xref>,
 <xref rid="B45-viruses-12-00276" ref-type="bibr">45</xref>]. However, the detailed mechanism of how antibody glycosylation impact Fc-effector functions remains unclear. It has been demonstrated that the reduced content of fucose can enhance ADCC activity [
 <xref rid="B46-viruses-12-00276" ref-type="bibr">46</xref>]. Various approaches, such as alpha-(1,6)-fucosyltransferase gene knockout, have been developed to manipulate antibody fucosylation to optimize ADCC activity [
 <xref rid="B47-viruses-12-00276" ref-type="bibr">47</xref>]. Glyco-engineering and protein engineering have emerged as the two main strategies to harness ADCC activity [
 <xref rid="B48-viruses-12-00276" ref-type="bibr">48</xref>].
</p>
